A Dual Biomarker TK1 Protein and CA125 or HE4-Based Algorithm as a Better Diagnostic Tool than ROMA Index in Early Detection of Ovarian Cancer

Author:

Cviič Diana12ORCID,Jagarlamudi Kiran3,Meglič Leon45,Škof Erik56ORCID,Zore Andrej4,Lukanović David4ORCID,Eriksson Staffan37,Osredkar Joško12ORCID

Affiliation:

1. Institute of Clinical Chemistry and Biochemistry, University Medical Centre Ljubljana, Zaloška c. 002, 1000 Ljubljana, Slovenia

2. Faculty of Pharmacy, University of Ljubljana, Aškerˇceva c. 7, 1000 Ljubljana, Slovenia

3. Research and Development Division, AroCell AB, 11151 Stockholm, Sweden

4. Division of Gynecology, Department of Gynecology, University Medical Centre Ljubljana, Zaloška c. 002, 1000 Ljubljana, Slovenia

5. Medical Faculty, University Ljubljana, Vrazov trg 1, 1000 Ljubljana, Slovenia

6. Institute of Oncology, Zaloška c. 002, 1000 Ljubljana, Slovenia

7. Department of Anatomy, Physiology & Biochemistry, Swedish University of Agricultural Science, VHC, 75007 Uppsala, Sweden

Abstract

Background: The early detection of ovarian cancer is presently not effective, and it is crucial to establish biomarkers for the early diagnosis of ovarian cancer to improve the survival of patients. Materials and methods: The aim of this study was to investigate the role of thymidine kinase 1 (TK1) in combination with CA 125 or HE4 to serve as a potential diagnostic biomarkers for ovarian cancer. In this study, a set of 198 serum samples consisting of 134 ovarian tumor patients and 64 healthy age-matched controls were analyzed. The TK1 protein levels in serum samples were determined using the AroCell TK 210 ELISA. Results: A combination of TK1 protein with CA 125 or HE4 showed better performance than either of them alone in the differentiation of early stage ovarian cancer from the healthy control group, but also a significantly better performance than the ROMA index. However, this was not observed using a TK1 activity test in combination with the other markers. Furthermore, the combination of TK1 protein and CA 125 or HE4 could differentiate early stage disease (stage I, II) more efficiently from advanced-stage (stage III, IV) disease (p < 0.0001). Conclusions: The combination of TK1 protein with CA 125 or HE4 increased the potential of detecting ovarian cancer at early stages.

Funder

University Clinical Centre Ljubljana

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Reference31 articles.

1. American Cancer Society (2022). Cancer Facts & Figures 2022, American Cancer Society.

2. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): A randomised controlled trial;Menon;Lancet,2021

3. A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma;Han;Gynecol Oncol.,2018

4. (2022). Cancer in Slovenia 2019, Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Slovenian Cancer Registry.

5. Ovarian Cancer: Epidemiology, Biology, and Prognostic Factors;Holschneider;Semin. Surg. Oncol.,2000

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3